B and opportunistic infections in patients with advanced

Size: px
Start display at page:

Download "B and opportunistic infections in patients with advanced"

Transcription

1 Placebo-Controlled Trial to Evaluate Zidovudine in Treatment of Human Immunodeficiency Virus Infection in Asymptomatic Patients With Hemophilia By Thomas C. Merigan, David A. Amato, James Balsley, Maureen Power, William A. Price, Sharon Benoit, Angela Perez-Michael, Alan Brownstein, Amy Simon Kramer, Doreen Brettler, Louis Aledort, Margaret V. Ragni, W. Abe Andes, Joan C. Gill, Jonathan Goldsmith, Sally Stabler, Natalie Sanders, George Gjerset, Jeanne Lusher, and the NHF-ACTG 0 Study Group One hundred ninety-three asymptomatic patients with hereditary coagulation disorders and human immunodeficiency virus (HIV) infection were studied in a controlled trial of zidovudine (ZDV) versus a placebo (with an average of 9.7 months on study). Pretreatment characteristics were well balanced between the placebo and drug-treated groups, including CD distributions, types of clotting disorders, transaminase abnormalities, and use of various hemostatic agents. At the time of analysis, 11 patients either were still receiving treatment or had previously reached an endpoint of disease progression while receiving treatment. Twenty-five patients withdrew voluntarily. The toxic effects noted included granulocytopenia and anemia, especially in older patients, and subjective symptoms of asthenia, malaise, and nausea, consistent with the known consequences of treatment with 00 mg ZDV five times daily. There was a trend toward more diagnoses of acquired immunodeficiency syndrome (AIDS), advanced or early AIDS-related complex (ARC), single ARC symptoms, or death in placebo recipients as compared with those receiving ZDV (22 v 1). Because older patients with hemophilia have more rapid disease progression, the same efficacy analysis was performed in the 89 ECAUSE ZIDOVUDINE (ZDV) prevented death B and opportunistic infections in patients with advanced acquired immunodeficiency syndrome (AIDS)- related complex (ARC) and AIDS, the National Institute of Allergy and Infectious Diseases AIDS Clinical Trial Group (ACTG) undertook a study of its efficacy in treating earlier stages of human immunodeficiency (HIV) infection. From the Center for AIDS Research, Stanford University School of Medicine, Stanford, CA; Harvard School of Public Health, Boston, MA; the National Institute of Allergy and Infectious Disease AIDS Program, Bethesda, MD; Research Triangle Institute, Research Triangle, NC; the National Hemophilia Foundation (NHF), New York, ht Medical Center of Central Massachusetts-Memorial, Wooster, MA; Mount Sinai Medical Center, New York, Nu; University of Pittsburgh, Pittsbqh, PA; Tulane University School of Medicine, New Orleans, LA; Great Lakes Hemophilia Foundation, Milwaukee, WI; University of Nebraska Medical Center, Omaha; Huntington Hospital Hemophilia Center, Pasadena, CA; and University of Washington, Seattle, WA. Submitted March 5, 1991; accepted April 18, Supported by NIAID Grant No. AI-8278 to the NHF, the Research Triangle Institute, the participating ACTUS, and Grant No. AI-9500 to the statistical center at Harvard. Address reprint requests to Thomas C. Merigan, MD, Center for AIDS Research, Stanford University Medical Center, Rm S-15 Grant Building Stanford, CA The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked advertisement in accordance with I8 U.S.C. section 17 solely to indicate this fact by The American Society of Hematology. OOo-971/91 j780-oo21$.00/0 patients aged more than 0 years who were receiving treatment. In this subgroup, there was a similar trend (1 1 v ). With regard to the most advanced problems of the infection among the older patients, there were five patients who were newly diagnosed with AIDS or died in the placebo group versus none in the ZDV group (P =.02) among the older patients. The pretreatment distribution of CD counts for the placebo and ZDV groups were similar, but patients aged more than 0 years had significantly (P <.09) fewer CD cells than patients aged less than 0 years. A beneficial ZDV effect is also supported by a trend toward higher CD counts (a 8-cell increase in the ZDV group at 2 weeks as compared with a four-cell increase in the placebo group) and a significant (P =.0) difference in weight gain in the ZDV patients aged more than 0 years (8 pounds) as compared with the older placebo patients (aged more than 0 years) (2 pounds) at week 2. The findings in the asymptomatic hemophilic patients aged more than 0 years support a useful effect of ZDV, which is similar to observations in the larger study of its use in asymptomatic, nonhemophilic patients. o 1991 by The American Society of Hematology. Because the pathogenesis of HIV infection in hemophilic patients might be different from that in other populations: we believed it important to evaluate treatment of asymptomatic HIV-infected individuals in this population. The original ACTG centers were located in areas of the highest population density of infected individuals, primarily homosexual males, inner-city intravenous (IV) drug abusers, or their consorts. Because hemophilia occurs uniformly throughout the population of the United States, these patients do not necessarily live close to ACTG centers. To obtain significant participation of the hemophilic population, the NIAID contracted with the National Hemophilia Foundation, a national advocacy group, to organize a nationwide group of centers to study the impact of early treatment with ZDV on the progression of HIV infection. An existing network of federally funded comprehensive hemophilic treatment centers was used. Ten regional centers were identified to work with the National Hemophilia Foundation, the outlying hemophilia centers, and the ACTG. Because of logistic difficulties inherent in the involvement of so many centers, the study started later than ACTG protocol 019, the nonhemophilic protocol for similar early treatment of HIV infection with ZDV. The primary endpoints of the hemophilia study were clinical progression of HIV infection, immune markers such as CD lymphocyte counts, weight change, and frequency of adverse reactions. We recognized that there was a preexisting high prevalence of posttransfusion hepatic disease in this population that could alter the pharmacokinetics of ZDV, its efficacy, and its side effects. Accordingly, a preliminary study of this dosage of ZDV was completed in hemophilic patients to insure that no interference with 900 Blood, Vol78, No (August 15). 1991: pp

2 ZIDOVUDINE IN TREATMENT OF HIV INFECTION 90 1 coagulation mechanisms, required clotting factor therapy, or major toxicity would be produced by the drug: MATERIALS AND METHODS Recruitment and entry cnteria. Patients were enrolled on an outpatient basis at hemophilia treatment centers (HTC) and treated at selected AIDS Clinical Trial Units (ACTU). Patients had to have well-established factor VI11 or IX deficiency, other coagulopathies (eg, factor V deficiency), or von Willebrand s disease, and had to have HIV antibody confirmed by Western blot. All patients were aged 12 years or older, and written consent of the parents or guardians was obtained for patients aged less than 18 years. Men and women were eligible; persons of reproductive potential were urged to practice adequate birth control. Subjects with progressive generalized lymphadenopathy as defined by the Centers for Disease Control (CDC) were not excluded. Patients had to have a Karnofsky performance of at least 90 unless performance was impaired by orthopedic complications of hemophilia, in which case a Karnofsky status as low as 0 was allowed. Patients had to have a CD cell count less than or equal to 500 cells/pl before randomization, a granulocyte count greater than 1,000 cells/pl, a platelet count greater than 75,000 cells/pl, a hematocrit greater than 0%, a serum creatinine level less than 1.5 times the upper limit of normal, and an alanine aminotransferase (ALT) level less than 10 times the upper limit of normal. Subjects with preexisting symptomatic HIV disease (except those with lymphadenopathy alone) and those with previous medication use or illness that suggested limited tolerance to ZDV were excluded from study. All patients signed a statement of informed consent approved by their local institutional review board. Eligible patients were randomized to therapy with orally administered ZDV at a dosage of 00 mg every hours while awake (5 doses per day) or to a placebo control arm. The ZDV dose was modified to 200 mg every hours when patients were awake (5 doses per day) in adolescent patients whose body surface area was less than 1.75 mz at the time of enrollment. Randomization and follow-up. Randomization occurred during evaluation at the ACTU, and therapy was started within 72 hours of randomization. Patients were assigned to the treatment or placebo arms on the basis of two stratification variables: CD cells less than 0OipL versus 00 to 500/pL and age 12 to 20 years versus age greater than 20 years. The randomization process used permeated blocks with dynamic balancing by institution to ensure that the difference between the numbers assigned to each treatment group in an ACTU did not exceed four. The treatment assignments were double blinded. Patients were examined weekly at their local HTC for the first 8 weeks, every other week for the next 8 weeks, and then every weeks thereafter. Patients were examined at the ACTU clinic twice yearly. Uniform toxicity management and criteria for monitoring disease progression were used. The accrual target plan was 58 patients to be entered into the study, with interim analyses of the data presented to the ACTG Data and Safety Monitoring Board (DSMB). The study was opened on February 25, In August 1989, the results of the first full interim analysis of patients in ACTG protocol 019 with initial T counts less than 500, which provided clear evidence of the beneficial effects of ZVD for this population, were made public. Because of the strong evidence that ZVD is beneficial in a similar population of patients, it was no longer considered ethical for patients on protocol 0 to continue to be treated with a placebo. At this time, entry of new patients to this study ceased; all patients in both treatment groups were crossed-over to ZDV therapy at a dose of 500 mg/d. At that time, 19 patients had been accrued. Follow-up on all patients continued, but only the data for patients up to the time they were crossed over to ZVD at 500 mg/d are included in this analysis because this represents the purest comparison of the treatment groups. The distributions of time to a critical event were estimated using the method of Kaplan and Meier. Comparisons between these distributions for the treatment groups were made using the log-rank test in an intent-to-treat analysis. Change from baseline in CD count and in weight was analyzed using two-sample t tests. Because of the comparison of ZDV with a placebo arm, all Pvalues are one-sided unless otherwise stated. The study was designed to have at least a 90% chance of detecting a reduction in the 2-year failure rate from 25% for placebo to 17% for ZDV, using a one-sided test and a 5% significance level. To achieve this goal, 58 patients (29 per arm) were to be entered and years of additional follow-up after the last patient was entered was required. Because accrual was terminated early and because follow-up time was necessarily shortened, the chance of detecting an effect of this magnitude was reduced to 20%. The chance of detecting a much larger reduction in the 2-year failure rate from 25% to 5% was only 8%. Spouse study. Spouses (steady sexual partners) of the patients on study were contacted by the hemophilia center staff, and of them agreed to be followed for possible HIV infection. This separate substudy involved its own consent form, serologic studies for HIV infection eveq months, and questionnaires regarding sexual activity. This survey was a unique opportunity to perform a blinded, prospective study of HIV seroconversion in a population whose sexual partners were HIV-positive and were randomly allocated to receive ZDV or placebo. The sexual partners underwent follow-up enzyme-linked immunosorbent assay (ELISA) testing at the time the corresponding patient left the study. In addition, all sexual partners were asked to return for follow-up ELISA testing at the time the study was unblinded. RESULTS The distributions of selected baseline characteristics of the study subjects are shown in Table 1. Ninety-one percent of entered patients were white, 2% had CD counts of less than 200 cells/pl, and 89% had hemophilia A. The median age was 1 years. The two treatment groups were well balanced with respect to distributions of baseline characteristics. Furthermore, there was no significant difference in these pretreatment factors according to age except that CD levels were significantly lower in the older patients (median 2 v 5, P <.09). Use of monoclonal antibody (MoAb)-purified factor VI11 concentrates, factor VIII, factor IX, and cryoprecipitates also were similar in the various groups. Table 2 shows the overall outcome of therapy for patients in the study. The voluntary withdrawal rate was 1% and was not different in ZDV and placebo groups. This rate is comparable to those observed in other studies of HIVinfected patients. The Pneumocystis prophylaxis regimen (aerosolized pentamidine) was used equivalently in both populations. Owing to the early termination of the study, as explained in the Materials and Methods section, the average number of months on study was 9.; this was not different between placebo and ZDV recipients. There were no differences in follow-up between the two groups as demonstrated by Kaplan-Meier plots in patients who were aged more than or less than 0 years of age (data not shown).

3 ~~ 902 MERIGAN ET AL Table 1. Selected Pretreatment Characteristics All Patients Age s0y Age > 0 y Characteristics Placebo ZDV Placebo ZDV Placebo ZDV Race White 17 Black 9 Other 7 1 a Median age (y) 0. CD Count < > a Median 28 Type of clotting disorder Hemophilia A 12 Hemophilia B 19 Other 2 1 a SGOT (x above ULM) 1.0 Monoclonal factor concentrate use Yes 7 No a Median quantity of Factor Vlll (U/mo),500 Factor IX (U/mo),500 Cryoprecipitate (bags/mo) 1 a ,000, ,500,00 15 a a I + Pi a I a ,000,000,500,000,500,500,500 2, ,000 5,00 0. a ,000 2,70 18 Table summcrizes the toxicities of the patients, including reported symptoms. As expected, the ZDV had more granulocyte toxicities as well as multiple hematologic toxicities (17% v nonr;, P <.mol). The notable symptomatic differences between ZDV and placebo recipients included asthenia (P =.05), malaise (P =.08), and nausea (P <.WOl). These complaints, as well as hematopoietic toxicities, were generally similar in the groups aged more than 0 years ahd less than 0 years (data not shown). In addition, the difference between the meau hemoglobin decrease iq the ZDV group aged more than 0 years as compared with placebo patients in the same group was Table 2. Overall Outcome for Patients on Study Status of All Patients Who Entered Study Placebo ZDV Patients on treatment at end of controlled trial phase Patients who died on study 1 Patients off treatment at end during con- trolled trial phase because of 21 ia 9 Clinical endpoint* Toxicity Voluntary withdrawal Average time (mo) on Pneumocystis prophylaxis (no. of patients) (12) (8) (20) Average time on study (mol *Development of AIDS or advanced AIDS-related complex. nearly statistically significant (P =.05) (data not shown). No special problems with hepatic dysfunction were observed despite the high incidence of underlying liver disease. Table summarizes the efficacy parameters in the study for all patients, as well as those aged less than or equal to 0 years and those aged more than 0 years. Thirty years was a convenient dividing line for separating older patients from younger patients because half of the patients were aged more than 0 years. By combining all disease progression landmarks in the study, including single ARC symptoms, the usefulness of ZDV was suggested. That the observed differences are not statistically significant (P =.19) is not surprising because of the small size of the study group and the short follow-up period. Neither were the differences significant by Kaplan-Meier analysis (P =.8) (Fig 1A). There was little evidence in the group aged 0 years or less for a ZDV effect. Indeed, there were more serious events in the ZDV group than in the placebo group, but the difference was not significant (P =.ll to.25). The only statistically significant changes observed occurred in patients aged more than 0 years. This group was analyzed separately because of recent epidemiologic analyses showing more rapid disease progression in this subgroup.8 In this group, ZDV treatment was associated with lower mortality and lesser progression to AIDS (P =.02). This difference was not affected by inclusion of events defined by time of onset of advanced ARC. Older patients had a poorer initial

4 ZIDOVUDINE IN TREATMENT OF HIV INFECTION 90 Table. Summary of Toxicities and Symptoms ously in the ACTG 019 study.' Figure 1B shows the Regimen Kaplan-Meier distribution of event-free intervals, related Placebo ZDV to our most statistically significant difference: failure to die or to progress to AIDS in the group aged more than 0 years when ZDV and placebo recipients were compared. The overall CD counts did not show a statistically 9 (5) 2 (2) 7 (8).09 significant difference between the placebo and ZDV groups, Type of --- Laboratory Toxicity n(%) n(%) n(%) PValue' Hematologic toxicities Hemoglobin < 8 g/dl Granulocytes <75O/kL 1 (8) O(0) 1 (17) <.0001 although at week 12 the older ZDV recipient group showed Platelets <5O,OOO/~L 5 () () 1 (1).7 Any a cell increase of 7lipL on the average. At week 2, the of the above 2 (1) () 2o (22),ool Multiple hematologic toxicities (2) 0 (0) ().05 ZDV group, as a whole, showed an increase in CD cell Hepatic Toxicitiest counts that was of borderline significance as compared with SGOT > 10 x upper limit (2) () O(0).12 the placebo group (P =.l) (most likely because of the SGPT > 10 x upper limit 7 () () ().71 incomplete sampling). At 2 weeks in the weight gain Alkaline phosphatase >5 x analysis, ZDV group as a whole had a 5-pound increase on upper limit 1 (1) O(0) 1 (1).8 the average as compared with start of therapy; older Bilirubin >5 x upper limit 1 (1) 1 (1) 0 (0) 1.0 patients had a weight gain averaging 8 pounds. The actual Any of the above 10 (5) 5 (5) 5 (5) 1.0 Multiple hepatic toxicities (2) () 0 (0).25 Symptoms* Anorexia (2) 0 (0) ().ll weight gain became significantly greater in the older placebo recipients at this time (P <.0) (Table 5). Apparently, compliance with treatment in this study was Asthenia (2) 0 (0) ().05 adequate, as shown by an analysis of the mean corpuscular Diarrhea () () () 1.0 volume (MCV) levels in drug and placebo recipients. The Dizziness 2 (1) l(1) l(1) 1.0 mean MCV values increased in the ZDV-treated group for Fever (2) l(1) 2 (2).1 the first 20 weeks and then stabilized at a higher level Headache 12 () () 8 (9).17 (averaging 105 to 110 fl) for the next 5 weeks. On the Insomnia 2(1) O(0) 2(2).2 other hand, placebo recipients showed no such increase Malaise I I () () 8 ('I.08 and were stable at a lower level (averaging 8 to 89 fl). This Myalgia l(1) 0 (0) 1 (1).8 result is similar to ACTG 019.' Nausea 1 (7) O(0) 1 (1) <.0001 Forty-two sexual partners of hemophilic patients en- Pain in abdomen 5 () () 2 (2) 1.00 rolled in the ACTG protocol 0 were recruited to partici- Rash l(1) 0 (0) l(1).8 Sample size pate in a study of their seroconversion. Forty-one of the enrolled subjects were female partners of male hemo- *From x2 test or Fisher's exact test. philics; one male sexual partner of a woman with von tupper limit refers to the upper limit of the normal range. Willebrand's disease was also enrolled. Forty-three percent Severe symtoms making patient unable to perform daily activity (grade and ). and 57% of enrolled subjects were sexual partners of patients randomized to receive ZDV and placebo, respectively. Baseline HIV ELISA testing was reported for 1 of prognosis7 as reflected by their lower CD levels On study the enrolled sexual partners; all were seronegative at entry. enro11ment, and the effect Of ZDV appears to be neater in this patient subgroup* Thus, even a group size Of 89 patients allowed demonstration of the beneficial effects of ZDV. The starting CD levels in the five patients who reached major endpoints in the group aged more than 0 years appear to be well distributed in the starting populations of that group. In all, the ACTG 0 data are compatible with the experience in asymptomatic patients reported previ- Twentyfive sexual partners had follow-up ELISA testing at the end of the controlled trial and remained seronegative. The mean time to follow-up ELISA testing was 9 months. DISCUSSION The results of this study are not clearly conclusive as to the usefulness of early ZDV treatment because of the Table. Summary of Efficacy Measures All Patients Age 5 0 y Age > 0 y Regimen Regimen Regimen Characteristic Pooled (n) Placebo ZDV PValue* Pooled (n) Placebo ZDV PValue+ Pooled (n) Placebo ZDV P Value* Death I. 1 0 I AIDS, death ,015 AIDS, advanced ARC, death I AIDS, advanced ARC, single ARC, death ,08 AIDS, advanced ARC, early ARC, single ARC, death Sample size Abbreviations: Advanced ARC, advanced AIDS-related complex; single ARC, single symptom of AIDS-related complex. *From long-rank test.

5 90 MERIGAN ET AL 2 I a DISTRIBUTION OF EVENT FREE INTERVALS 1 z E I 0.0! I I I I I I I I I a U a /B ::: MONTHS IN STUDY MONTHS IN STUDY Fig 1. (A) Kaplan-Meier plot of death, onset of AIDS, or ARC diagnosis or a single ARC symptom for the entire study group. Log rank test: P =.8. (B) Kaplan-Meier plot of occurrence of death or diagnosis of AlDSfor patients aged more than 0 years. Regimen: (-) placebo; (----) ZDV. partial (0%) accrual of the target population and the early termination of the study for ethical reasons. In contrast to results in younger patients, results in patients aged more than 0 years, who initially usually had lower CD cells, ZDV appears to have decreased the incidence of death and progression to AIDS. Therefore, these results support the findings of protocol 019' to the extent that could be expected owing to the short follow-up of the numbers of patients studied. Considering the side effects observed in the 1,500-mg arm in protocol 019, neither is it surprising that there was a higher rate of hematologic toxicity and nausea among ZDV recipients in this trial. Because ZDV is glycosylated in the liver, we were concerned that the preexisting hepatic disease would influence either the toxicity or efficacy of this therapy; however, this did not appear to be true. There were no differences in characteristics between the placebo and the ZDV groups at entry that would explain the apparent diminished disease progress in the older patients who received ZDV. The analyses of CD counts data unfortunately are limited by some missing values because patients had to be followed at many different hemophilia centers and ACTU sites. The trends toward higher CD counts in the treated group, including those who were older, are of interest, as is the increased weight gain in the older ZDV-treated patients. These trends, however, could be influenced by potential differences in the dropout rate in the two arms. Because weight gain also was not consistently documented, the patients in the drug arm may have preferentially dropped out because of weight loss due to nausea. If so, the Table 5. Change in CD Counts and Body Weight Related to Therapy All Patients s0y >0y Parameter Placebo ZDV PValue Placebo ZDV PValue Placebo ZDV PValue _ ~ ~ _ CD count Week 0 Median n Week 12 Median n Week 2 Median n Week 52 Median n Weight Week 0 Median NS n Week 2 Median NS n

6 ZIDOVUDINE IN TREATMENT OF HIV INFECTION 905 Table. Comparative Results of ZDV Therapy in Controlled Trials No. of Average Months Trial Patients of Therapy Results (Pvalues) Stage of Disease ~~~ ~ ACTG 019' 1,8 1.1 AIDS, advanced ARC (both ZVD doses.002) Asymptomatic T <500 ACTG 0 (present study) 19 9 Y2 J. t*, AIDS (> 0-y strata,.015) Asymptomatic T < 500 ACTG 01' t*, AIDS, advanced ARC (.002) Early ARC BW phase 11' 282 %.1 t* (.001) AIDS, advanced ARC *Dagger denotes death. estimation of the true mean percentage weight gain would not be representative because patients with negative changes would not be represented. Thus, the surrogate marker results for disease progression from this study were disappointing. Table summarizes all ZDV controlled trials that have been reported. It is of methodologic interest that in patients who are studied early in disease death is an unlikely endpoint, even if substantial numbers of patients are studied, as in ACTG 019. Although conclusions regarding usefulness of therapy are less definitive without a demonstrated difference in survival, death will probably not be used as the primary endpoint in future trials. For more efficient analysis of trials, we must determine which of the minor symptoms, surrogate markers, or signs of disease progression with which the action of drugs in this infection can be compared are most reliable. We hope that ongoing clinical trial efforts together with analyses of studies such as ours will clarify this issue. Owing to the early termination of accrual and the limited duration of follow-up, this study had little sensitivity to detect moderate or even fairly large effects of ZDV. If the study could have been completed as planned, with three times as many patients and adequate follow-up, we might have been able to identify beneficial effects of ZDV, both overall and for the subgroup of patients aged less than 0 years. Further study of the usefulness of these doses of ZDV in younger asymptomatic hemophilic patients appears prudent. Finally, in the spousal study, our ability to demonstrate a useful effect of ZDV in prevention of transmission is not surprising considering the short follow-up and the small numbers of patients entered in the study. It is also consistent with previous studies, indicating that seroconversion of partners occurs infrequently." Results of this study clearly support the conclusions of ACTG 019 and suggest that in future trial designs pooling certain data or conducting studies in certain subpopulations may yield drug efficacy information with fewer patients. This may be important as we begin to study more and more methods and comparisons with active drug controls in these and other HIV-infected populations. An important benefit from this study is that through their enrollment in this study 1% of all persons with hemophilia in the United States, their comprehensive care centers, and their national advocacy group have become more knowledgeable about AIDS treatment trials. This has led to the increased involvement of hemophilia investigators in the national ACTG meetings and their sponsorship of and involvement in ACTG protocol 1, a phase 1-2 study of combination antiretrovirals. Integrating these institutions and their patients more readily into other existing or new ACTG trials while retaining their social support network and optimum medical care should now be possible. ACKNOWLEDGMENT This study would not have been possible without the involvement of many physicians, nurses, and pharmacists who care for hemophilic patients throughout the United States. We are grateful to them and to others, including Dr Thomas Peterman and Kathleen Patishall for help in the original protocol design and Ranny Dafni for help in data analysis. The NHF-ACTG 0 Study Group includes: National Hemophilia Foundation: Richard Atwood, MPH, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC; Karen Bloodgood, RN, University of North Carolina, Chapel Hill, NC; Marianne Casicino, RN, Hemophilia Center of Western Pennsylvania, Pittsburgh, PA; Joann Deutsche, RN, BSN, Rehabilitation Institute of Chicago, Chicago, IL; Patricia Forand, RN, Worchester Memorial Hospital, Worchester, MA; David Green, MD, PhD, Rehabilitation Institute of Chicago, Chicago, IL; Ralph A. Guppa, MD, Childt m 's Hospital Medical Center, Cincinnati, OH; Wahid Hanna, MD, University of Tennessee Medical Center, Knoxville, TN, William E. Hathaway, MD, University of Colorado Health Sciences Center, Denver, CO; Edward J. Hershgold, MD, University of Utah Medical, Salt Lake City, UT; Naomi Israel, RN, George Washington University Medical Center, Washington, DC; Kimberly Jackson, RN, Huntington Hospital Hemophilia Center and Orthopaedic Hospital Hemophilic Center, Pasadena, CA, Christina Johnson, MD, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC; James Keyes, Puget Sound Blood Center, Seattle, WA; E. W. Louvrian, MD, Oregon Health Science University, Portland OR; Rita Lovely, RN, University of Nebraska, Omaha, NE; Jeannia MacFarland, RN, University of Tennessee Medical Center, Knoxville, TN, Barbara Miller, RN, BSN, Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, Margot L. Nelson, MSN, University of Minnesota, Minneapolis, MN; John P. Olson, MD, Mary M. Gooley Hemophilia Center, Rochester, Ny, Nan E. Rausch, MD, Albany Medical Center, Albany, Ny; Brenda Riske, RN, University of Colorado Health Sciences Center, Denver, CO; Esther Rose, MD, Mount Sinai Medical Center, New York, Ny, Karen Sachse, RN, George Washington University Medical Center, Washington, DC; Parvin Saidi, MD, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ; Stephanie Seremetis, MD, Mount Sinai Medical Center, New York, NY; Amy Shapiro, MD, Indiana Comprehensive Hemophilia Center, Indianapolis, I N Sandor S. Shapiro, MD, Cardeza Foundation Hemophilia Center, Philadelphia, PA; Betty Song, RN, Puget Sound Blood Center, Seattle, WA, Stephen Spector, MD, University of California, San Diego, San Diego, CA; John Sprandio, MD, Cardeza Foundation Hemophilia Center, Philadelphia, PA, Patricia Timmons, RN, Great Lakes Hemophilia Foundation, Milwaukee, WI; Gilbert C. White, MD, University of North Carolina, Chapel Hill, NC; The ACTG 0 Study Group consists of Michael T. Brady, MD, Division of Infectious Diseases, Depart-

7 90 MERIGAN ET AL ment of Pediatrics, Ohio State University College of Medicine, Columbus, OH; Lynda Costanzo, RN, BS, George Washington University Hemophilia Comprehensive Care Center, Washington, DC, M. Elaine Eyster, MD, Pennsylvania State University School of Medicine, Hershey, PA; Kenneth H. Fife, MD, PhD, Indiana University School of Medicine, Indianapolis, IN, David J. Gocke, MD, Robert Wood Johnson Medical School, New Brunswick, NJ; JoeAnn Goldsmith, MD, Northwestern University Medical School, Chicago, Illinois; Ralph A. Gruppo, MD, University of Cincinnati Childrens Hospital, Research Foundation, Cincinnati, OH; Monto Ho, MD, Department of Infectious Diseases & Microbiology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, Michael M. Lederman, MD, Case Western Reserve University School of Medicine, Cleveland, OH; Kenneth McIntosh, MD, Children s Hospital, Boston, MA, Professor of Pediatrics, Harvard Medical School, Boston, MA, Margot L. Nelson, RN, MSN, University of Minnesota, Minneapolis, MN; Richard C. Reichman, MD, Department of Medicine, School of Medicine and Dentistry, Rochester, NY; Douglas Richman, MD, Department of Pathology and Medicine, University of California at San Diego Medical Center, Veterans Administration Medical Center, La Jolla, CA; Henry S. Sacks, PhD, MD, Mount Sinai Medical Center, New York, NY; Charles van der Horst, MD, Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, and Karen Vedrenne, BSN, Louisiana Comprehensive Hemophilia, New Orleans, LA. 1. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS, Murphy RL, Harday WD, Soeiro R, Fischl MA, Bartlett JF, Merigan TC, Hyslop NE, Richman DD, Valentine FT, Corey L, and the Aids Clinical Trials Group of the National Allergy and Infectious Diseases: Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD-positive cells per cubic millimeter. N Engl J Med 22:91, Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberdine PA, Laskin 01, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D, and the AZT Collaborative Working Group: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 17:185,1987. Eyster M, Gail MH, Ballard JO, Al-Mondhiry H, Goedert JJ: Natural history of human immunodeficiency virus infections in hemophiliacs: Effects of T-cell subsets, platelet counts, and age. Ann Intern Med 1071,1987. Morse GD, Portmore A, Olson J, Taylor C, Plank C, Reichman RC Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob Agents Chemother, Zelem M: The randomization and stratification of patients to clinical trials. J Chron Dis 27:5, 197 REFERENCES. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 5:57, Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Can Chemother Rep 50:1, Goddert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White GC, Drummond JE, Vaidya K, Eyster E, Ragni HV, Lederman MM, Cohen AR, Bray GL, Rosenberg PS, Freidman RM, Hilgartner MW, Blattner WA, Droner B, Gail MH: A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 21:111, Fischl MA, Parker CB, Pettinelli C, Wolfson M, Hirsch MS, Collier AC, Causey D, Ho M, Richman DD, Fuchs E, Merigan TC, Reichman RC, Gold J, Steigbigel N, Leoung GS, Rasheed S, Tsiatis A, and the AIDS Clinical Trials Group of the National Allergy and Infectious Diseases: The efficacy and safety of a lower daily dose of zidovudine in the treatment of patients with AIDS: A randomized controlled trial. N Engl J Med 2:1011, Ragni MV, Kingsley LA, Nimorwicz P, Mann DL, Gupta P, Rinaldo CR Heterosexual HIV transmission: Lack of relation to serum P2 antigens, T number, clinical diagnosis, or duration of HIV exposure. J AIDS 2557,1989

National Bureau for Academic Accreditation And Education Quality Assurance PUBLIC HEALTH

National Bureau for Academic Accreditation And Education Quality Assurance PUBLIC HEALTH 1 GEORGE WASHINGTON UNIVERSITY WASHINGTON DC B Athletic Training 1 MA B 1 BROWN UNIVERSITY PROVIDENCE RI B EAST TENNESSEE STATE UNIVERSITY JOHNSON CITY TN B 3 HUNTER COLLEGE NEW YORK NY B 4 UNIVERSITY

More information

Number of Liver Transplants Performed 2003-2004 Updated October 2005

Number of Liver Transplants Performed 2003-2004 Updated October 2005 PEDIATRIC CENTERS PEDIATRIC TRANSPLANT CENTERS Number of Liver Transplants Performed 2003-2004 Updated October 2005 University of Alabama Hospital, Birmingham, AL 3 2 1 University Medical Center, University

More information

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2015

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2015 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2015 ANESTHESIOLOGY- 4 Beth Israel Deaconess Medical Center, Boston MA Oregon Health & Science University, Portland OR St. Louis Children s

More information

CHAPTER 2 MODELING THE PROGRESSION OF HIV-INFECTED PERSONS TO AIDS

CHAPTER 2 MODELING THE PROGRESSION OF HIV-INFECTED PERSONS TO AIDS CHAPTER 2 MODELING THE PROGRESSION OF HIV-INFECTED PERSONS TO AIDS Since people who are infected with HIV seem to progress through various stages or phases towards AIDS and death due to AIDS (Redfield

More information

U.S. NEWS RANKING OF MEDICAL COLLEGES 2012

U.S. NEWS RANKING OF MEDICAL COLLEGES 2012 U.S. NEWS RANKING OF MEDICAL COLLEGES 2012 http://grad schools.usnews.rankingsandreviews.com/best graduate schools/top medicalschools/research rankings Best Medical Schools: Research To see full rankings,

More information

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR CLASS OF Anesthesiology - 9. Dermatology - 3

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR CLASS OF Anesthesiology - 9. Dermatology - 3 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR CLASS OF 2008 Anesthesiology - 9 Beth Israel Deaconess Medical Center, Boston MA George Washington University, Washington DC NYP Hospital-Columbia

More information

Anemia HIV/AIDS. Anemia has been associated with progression to AIDS and shorter survival times for HIV + patients.

Anemia HIV/AIDS. Anemia has been associated with progression to AIDS and shorter survival times for HIV + patients. Anemia has been associated with progression to AIDS and shorter survival times for HIV + patients. VI Anemia & HIV/AIDS Key Points Multiple factors, both disease-related and treatment-related, can cause

More information

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form. General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary

More information

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR CLASS OF 2010. Anesthesiology - 9. Dermatology - 1. Emergency Medicine - 12

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR CLASS OF 2010. Anesthesiology - 9. Dermatology - 1. Emergency Medicine - 12 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR CLASS OF 2010 Anesthesiology - 9 Beth Israel Deaconess Medical Center, Boston MA Ohio State University Medical Center, Columbus OH Stanford

More information

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2011

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2011 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2011 ANESTHESIOLOGY- 9 Beth Israel Deaconess Med Center, Boston MA Massachusetts General Hospital, Boston MA (2) Stanford University Programs,

More information

TABLE 37. Higher education R&D expenditures at institutions with a medical school, by state, institutional control, and institution: FY 2011

TABLE 37. Higher education R&D expenditures at institutions with a medical school, by state, institutional control, and institution: FY 2011 TABLE 37. Higher education R&D at institutions with a medical school, by state, institutional Alabama U. AL, Birmingham 503,698 369,116 U. South AL 42,233 16,810 Arizona U. AZ 610,565 160,136 Arkansas

More information

Frequently Asked Questions (FAQs)

Frequently Asked Questions (FAQs) Frequently Asked Questions (FAQs) Research Rationale 1. What does PrEP stand for? There is scientific evidence that antiretroviral (anti-hiv) medications may be able to play an important role in reducing

More information

Promacta. Promacta (eltrombopag) Description

Promacta. Promacta (eltrombopag) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.15 Subject: Promacta Page: 1 of 6 Last Review Date: September 18, 2015 Promacta Description Promacta

More information

treating the flu with Rapivab (peramivir injection) 1

treating the flu with Rapivab (peramivir injection) 1 For flu patients in the emergency department who may not be appropriate for oral treatment 1,2 It only takes to be Infl uenza epidemics cause approximately 225,000 hospitalizations and 23,000 deaths in

More information

National Bureau for Academic Accreditation And Education Quality Assurance LINGUISTICS # UNIVERSITY CITY STATE DEGREE MAJOR SPECIALTY RESTRICTION

National Bureau for Academic Accreditation And Education Quality Assurance LINGUISTICS # UNIVERSITY CITY STATE DEGREE MAJOR SPECIALTY RESTRICTION 1 UNIVERSITY OF MASSACHUSETTS - BOSTON ~ BOSTON MA M 1 ARIZONA STATE UNIVERSITY - TEMPE TEMPE AZ MD ~ M for Linguistics is for Residential Program ONLY. The online option is not ~ M in Linguistics is for

More information

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2012

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2012 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2012 ANESTHESIOLOGY- 10 Beth Israel Deaconess Med Center, Boston MA Brigham & Women s Hospital, Boston MA Johns Hopkins Hospital, Baltimore

More information

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION

HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol Title: A5322, Version 2.0, 01/28/15 Long-term Follow-up of Older HIV-infected Adults in the ACTG: Addressing

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hunter syndrome is a rare genetic disease which mainly affects males of all ethnicities. The incidence rate ranges from 0.6 to

More information

HEPATITIS B VACCINATION KIT

HEPATITIS B VACCINATION KIT THE UNIVERSITY OF SOUTHERN INDIANA HEPATITIS B VACCINATION KIT Please bring this booklet to your scheduled Hepatitis B Vaccination appointment and present to your physician. Environmental Health and Safety

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

HIV/AIDS Barbara Russell RN, MPH, CIC

HIV/AIDS Barbara Russell RN, MPH, CIC HIV/AIDS - 2009 Barbara Russell RN, MPH, CIC Schematic of a Chronic Incurable Infection Incidence (new infections) Prevalence Deaths (outflow) Global summary of the AIDS epidemic, December 2007 Number

More information

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2014

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2014 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2014 ANESTHESIOLOGY- 8 Massachusetts General Hospital, Boston MA Medical College of Wisconsin Affiliated Hospitals, Milwaukee WI NYP Hospital-Columbia

More information

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2013

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2013 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR 2013 ANESTHESIOLOGY- 8 Barnes-Jewish Hospital, St. Louis MO Einstein/Montefiore Medical Center, Bronx NY Hershey Medical Center/Penn State,

More information

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis Guideline Background... 2 Screening... 2 Recommendations... 2 Ordering and consent... 2 Indications for Periodic HIV Screening...

More information

NATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

NATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma NATIONAL CANCER INSTITUTE Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Basic Trial Information Phase Type Status Age Sponsor Protocol IDs Phase

More information

A 38 year old female presents with inability to sleep. Through the history, the husband

A 38 year old female presents with inability to sleep. Through the history, the husband RUNNING HEAD: Iron Replacement and Restless Leg Syndrome 1 The Clinical Scenario: A 38 year old female presents with inability to sleep. Through the history, the husband states he has noticed her legs

More information

Clinical Trials Glossary

Clinical Trials Glossary Clinical Trials Glossary ADME: an acronym for absorption, distribution, metabolism and elimination. ADME studies determine how a drug is absorbed by the body, the chemical changes that it may undergo and

More information

Mayo Clinic, Rochester, MN; 6 University of Chicago Medical Center, Chicago, IL; 7

Mayo Clinic, Rochester, MN; 6 University of Chicago Medical Center, Chicago, IL; 7 A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit G Garcia-Manero 1,

More information

VIH/SIDA en Pediatría: Epidemiología Mundial, Transmisión Perinatal, Manejo Integral.

VIH/SIDA en Pediatría: Epidemiología Mundial, Transmisión Perinatal, Manejo Integral. VIH/SIDA en Pediatría: Epidemiología Mundial, Transmisión Perinatal, Manejo Integral. Juan Carlos Salazar, M.D. Universidad de Connecticut, EE.UU. End-1998 global estimates Children (

More information

Anesthesiology - 9. Dermatology - 3. Emergency Medicine Family Medicine -13

Anesthesiology - 9. Dermatology - 3. Emergency Medicine Family Medicine -13 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR CLASS OF 2007 Harbor-UCLA Med Ctr, Los Angeles CA Univ Rochester/Strong Mem, Rochester NY (6) Western Pennsylvania Hosp, Pittsburgh PA Hospital

More information

Informed Consent: Valcyte (valganciclovir) Treatment for Chronic Fatigue Syndrome. From Richard Podell, M.D., MPH, August 3, 2014

Informed Consent: Valcyte (valganciclovir) Treatment for Chronic Fatigue Syndrome. From Richard Podell, M.D., MPH, August 3, 2014 Informed Consent: Valcyte (valganciclovir) Treatment for Chronic Fatigue Syndrome Background: From Richard Podell, M.D., MPH, August 3, 2014 Currently there are no proven effective treatments for chronic

More information

List of low tuition universities in the USA. 1. Louisiana Tech University, LA Total Cost to. International Students: $17,472

List of low tuition universities in the USA. 1. Louisiana Tech University, LA Total Cost to. International Students: $17,472 A list of top universities in the US with low tuition fees for international students. So please find below a comprehensive list of low tuition universities in the US with their respective tuition fees.

More information

Nursing Home Costs Average $181 Per Day in U.S.

Nursing Home Costs Average $181 Per Day in U.S. Nursing Home Costs Average $181 Per Day in U.S. 2003 MetLife Market Survey Reports Costs Vary Widely from Region to Region The average nursing home cost in the United States is $181 per day for a private

More information

ALBERTA IMMUNIZATION POLICY GUIDELINES

ALBERTA IMMUNIZATION POLICY GUIDELINES ALBERTA IMMUNIZATION POLICY GUIDELINES Hepatitis Vaccines. Hepatitis A Vaccines Refer to the vaccine product monograph and the Canadian Immunization Guide for further Product monographs are available on

More information

Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care

Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care Using HIV Surveillance Data to Calculate Measures for the Continuum of HIV Care Anna Satcher Johnson, MPH Symposium on Measuring the HIV Care Continuum Center for AIDS Research University of Washington

More information

Study Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch

Study Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch BLA: STN 103471 Betaseron (Interferon β-1b) for the treatment of secondary progressive multiple sclerosis. Submission dated June 29, 1998. Chiron Corp. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D.

More information

The Most Affordable Cities For Individuals to Buy Health Insurance

The Most Affordable Cities For Individuals to Buy Health Insurance The Most Affordable Cities For Individuals to Buy Health Insurance Focusing on Health Insurance Solutions for Millions of Americans Copyright 2005, ehealthinsurance. All rights reserved. Introduction:

More information

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR CLASS OF 2009. Anesthesiology - 10. Dermatology - 4

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR CLASS OF 2009. Anesthesiology - 10. Dermatology - 4 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE MATCH RESULTS FOR CLASS OF 2009 Anesthesiology - 10 Hospital of the University of Pennsylvania, Philadelphia PA (2) Johns Hopkins Hospital, Baltimore MD University

More information

Liver transplant programs that perform living donor transplants

Liver transplant programs that perform living donor transplants Liver transplant programs that perform living donor transplants Based on OPTN data as of July 29, 2016. Data subject to change based on future data submission or correction. For more information about

More information

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,

More information

University of Alabama School of Medicine 2016 Match Results by PGY1 Location

University of Alabama School of Medicine 2016 Match Results by PGY1 Location University of Alabama School of 206 Match Results by PGY Location Institution * City * State* Program * Count All Children s Hospital St. Petersburg FL Baptist Health System Birmingham AL General Surgery

More information

Title: Public Health Reporting and National Notification for Hepatitis A

Title: Public Health Reporting and National Notification for Hepatitis A 11-ID-02 Committee: Infectious Disease Title: Public Health Reporting and National Notification for Hepatitis A I. Statement of the Problem The hepatitis A case definition is in need of revision to better

More information

SCHEDULE. Medical College of Alabama, Birmingham. University of Arkansas School, Little Rock. Loma Linda University School, Loma Linda.

SCHEDULE. Medical College of Alabama, Birmingham. University of Arkansas School, Little Rock. Loma Linda University School, Loma Linda. MEDICAL PRACTITIONERS ORDINANCE () Applied to Ascension by Chapter 5 of the 1950 Revised Edition of the Laws MEDICAL PRACTITIONERS (ASCENSION) REGULATIONS In exercise of the powers conferred upon the Governor

More information

Challenges and Progress: Implementing HIV Screening in Health-Care Settings

Challenges and Progress: Implementing HIV Screening in Health-Care Settings Challenges and Progress: Implementing HIV Screening in Health-Care Settings Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV/AIDS,

More information

Hepatitis A The Basics

Hepatitis A The Basics HEPATITIS A VIRUS Hepatitis A The Basics Patrick Lynch, MD Assistant Professor of Medicine Northwestern University HEPATITIS A - CLINICAL FEATURES Jaundice by

More information

Open in: NKI/AvL: J.P. de Boer UMCU: M.C. Minnema en VUMC: J.M. Zijlstra

Open in: NKI/AvL: J.P. de Boer UMCU: M.C. Minnema en VUMC: J.M. Zijlstra MSD, MK-3475-087 study: A Phase II clinical trial of MK-3475 (pembrolizumab) in subjects with relapsed or refractory (R/R) classical Hodgkin Lymphoma (chl) Open in: NKI/AvL: J.P. de Boer (j.d.boer@nki.nl),

More information

SYNOPSIS. Risperidone: Clinical Study Report CR002020

SYNOPSIS. Risperidone: Clinical Study Report CR002020 SYNOPSIS Protocol No.: CR002020 Title of Study: in the prevention of relapse: a randomized, double-blind, placebo-controlled trial in children and adolescents with conduct and other disruptive behavior

More information

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP) Guideline

HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP) Guideline HIV (Human Immunodeficiency Virus) Screening and Pre-Exposure Prophylaxis (PrEP) Guideline Background... 2 Screening Recommendations...2 HIV Test Ordering and Consent... 2 Indications for Periodic HIV

More information

EMBARGOED UNTIL OCTOBER 3, PM

EMBARGOED UNTIL OCTOBER 3, PM EMBARGOED UNTIL OCTOBER 3, 2016 12PM New Avon Foundation-Funded Study: BLACK: WHITE DISPARITIES IN BREAST CANCER MORTALITY IN THE 50 LARGEST CITIES IN THE UNITED STATES, 2005-2014 Conducted by Sinai Urban

More information

CIGNA LIFESOURCE Transplant Network Centers of Excellence

CIGNA LIFESOURCE Transplant Network Centers of Excellence CIGNA LIFESOURCE Transplant Network Centers of Excellence Alabama Arizona California University of Alabama at Birmingham Medical Center (adult and pediatric heart, adult lung, adult and pediatric liver,

More information

REPORT: 2007-08 DEMOGRAPHIC SURVEY OF UNDERGRADUATE AND GRADUATE PROGRAMS IN COMMUNICATION SCIENCES AND DISORDERS

REPORT: 2007-08 DEMOGRAPHIC SURVEY OF UNDERGRADUATE AND GRADUATE PROGRAMS IN COMMUNICATION SCIENCES AND DISORDERS 1 Council of Academic Programs in Communication Sciences & Disorders (CAPCSD) REPORT: 2007-08 DEMOGRAPHIC SURVEY OF UNDERGRADUATE AND GRADUATE PROGRAMS IN COMMUNICATION SCIENCES AND DISORDERS Conducted

More information

1 of Nov-16 5:41 PM

1 of Nov-16 5:41 PM 1 of 39 22-Nov-16 5:41 PM 2 of 39 22-Nov-16 5:41 PM Susan Whiting University of Saskatche Susan.whiting@usask.c Protocol for a 24-Week Randomized Controlled Study of Once-Daily Oral Dose of Flax Lignan

More information

Glossary of HIV/AIDS-Related Terms

Glossary of HIV/AIDS-Related Terms Chapter 48 Glossary of HIV/AIDS-Related Terms acquired immunodeficiency syndrome (AIDS): A disease of the body s immune system caused by the human immunodeficiency virus (HIV). AIDS is characterized by

More information

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2): Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS

More information

PROTOCOL SYNOPSIS BMT CTN 1401 PROTOCOL

PROTOCOL SYNOPSIS BMT CTN 1401 PROTOCOL PROTOCOL SYNOPSIS BMT CTN 1401 PROTOCOL Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination

More information

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School

More information

States, Capitals, & US Regions

States, Capitals, & US Regions States, Capitals, & US Regions State, County, and City A state is a nation or territory considered as an organized political community under one government. A county is a political and administrative division

More information

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner

More information

EMBARGOED FOR RELEASE UNTIL 5:00 P.M. ET, MONDAY, JUNE 14, 2010

EMBARGOED FOR RELEASE UNTIL 5:00 P.M. ET, MONDAY, JUNE 14, 2010 EMBARGOED FOR RELEASE UNTIL 5:00 P.M. ET, Appendix Table 1. Community-Based Medical Schools* Medical School of North Dakota of South Dakota Sanford School of Medicine Michigan State of Hawai'i John A.

More information

Association of American Medical College-Affiliated, Liaison Committee on Medical Education-

Association of American Medical College-Affiliated, Liaison Committee on Medical Education- Supplemental Digital Appendix 1 Association of American Medical College-Affiliated, Liaison Committee on Medical Education- Accredited U.S. Medical Schools Included in an Assessment of Clerkship Grading

More information

Two-Day Regimen of Acyclovir for Treatment of Recurrent Genital Herpes Simplex Virus Type 2 Infection

Two-Day Regimen of Acyclovir for Treatment of Recurrent Genital Herpes Simplex Virus Type 2 Infection M A J O R A R T I C L E Two-Day Regimen of Acyclovir for Treatment of Recurrent Genital Herpes Simplex Virus Type 2 Infection Anna Wald, 1,2,3 David Carrell, 3 Michael Remington, 3 Elizabeth Kexel, 3 Judy

More information

Entering a Clinical Trial

Entering a Clinical Trial Entering a Clinical Trial Is It Right for You? Paula Chandoha, Chandoha Productions About This Program THIS AUDIOVISUAL PROGRAM AND BOOKLET WERE produced by Dana-Farber Cancer Institute in collaboration

More information

First self-administered antibody therapy for HIV in late-stage clinical trials

First self-administered antibody therapy for HIV in late-stage clinical trials First self-administered antibody therapy for HIV in late-stage clinical trials Investor Presentation December 2016 1 Forward-Looking Statements This presentation includes forward-looking statements and

More information

Belgium. Canada. California

Belgium. Canada. California Belgium Ghent University Ghent, Flanders, Belgium PI: Dr. Bart Loeys Coordinator: Sylvia De Nobele Phone Number: 32-9-332.63.39 E-mail address: sylvia.denobele@ugent.be Canada Hospital For Sick Children

More information

Medical School Math Requirements and Recommendations

Medical School Math Requirements and Recommendations Medical School Math Requirements and Recommendations All information in this document comes from the 2010-2011 Medical School Admission Requirements book (commonly known as the MSAR). Students should check

More information

ONTARIO MINISTRY OF HEALTH

ONTARIO MINISTRY OF HEALTH ONTARIO MINISTRY OF HEALTH GUIDELINES FOR MANAGEMENT OF CONTACTS OF CASES OF INVASIVE GROUP A STREPTOCOCCAL DISEASE (GAS) INCLUDING STREPTOCOCCAL TOXIC SHOCK SYNDROME (STSS) AND NECROTIZING FASCIITIS Disease

More information

ROUTINE HIV SCREENING: A REVIEW OF THE EVIDENCE FROM 2007 TO 2010 SEPTEMBER 2010

ROUTINE HIV SCREENING: A REVIEW OF THE EVIDENCE FROM 2007 TO 2010 SEPTEMBER 2010 ROUTINE HIV SCREENING: A REVIEW OF THE EVIDENCE FROM 2007 TO 2010 SEPTEMBER 2010 Since the USPSTF conducted its focused update of the evidence on routine HIV screening in 2007: earlier initiation of antiretroviral

More information

5.07.09. Aubagio. Aubagio (teriflunomide) Description

5.07.09. Aubagio. Aubagio (teriflunomide) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)

More information

Metastatic Triple Negative Breast Cancer: The TNT Trial Comparing Two Older Drugs Head to Head

Metastatic Triple Negative Breast Cancer: The TNT Trial Comparing Two Older Drugs Head to Head Metastatic Triple Negative Breast Cancer: The TNT Trial Comparing Two Older Drugs Head to Head The TNT clinical trial was conducted in the United Kingdom with enrollment beginning August 2008, and recruitment

More information

Health of Wisconsin. Children and young adults (ages 1-24) B D. Report Card 2013. July 2010

Health of Wisconsin. Children and young adults (ages 1-24) B D. Report Card 2013. July 2010 Health of Wisconsin Summary Grades Life stage Health grade Health disparity grade Infants (less than 1 year of age) C D Children and young adults (ages 1-24) B D Working-age adults (ages 25-64) B C Older

More information

A B C D E. Boston MA NA Environmental Health (MPH; PhD) Environmental/Occupational Health and Safety (BS) Environmental & Occupational Health (BS);

A B C D E. Boston MA NA Environmental Health (MPH; PhD) Environmental/Occupational Health and Safety (BS) Environmental & Occupational Health (BS); 2 3 4 5 6 7 8 9 0 2 3 4 5 6 7 8 9 20 Alabama A&M University Norman AL Environmental Science (BS) Benedict College Columbia SC Environmental (BS) Bloomsburg University PA Physics (BS) Boise State University

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of

More information

Home Telehealth: Enhancing Access to MS Health Care

Home Telehealth: Enhancing Access to MS Health Care Home Telehealth: Enhancing Access to MS Health Care Jodie K. Haselkorn, MD, MPH Director, MS Center of Excellence West Professor, Rehabilitation Medicine Adjunct Professor, Epidemiology University of Washington

More information

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014

Didactic Series. Updated Post-Exposure Prophylaxis (PEP) Guidelines. Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 Didactic Series Updated Post-Exposure Prophylaxis (PEP) Guidelines Daniel Lee, MD UCSD Medical Center, Owen Clinic January 9, 2014 ACCREDITATION STATEMENT: University of California, San Diego School of

More information

Introducing the PrEP Package for Enhanced HIV Prevention: A Practical Guide for Clinicians

Introducing the PrEP Package for Enhanced HIV Prevention: A Practical Guide for Clinicians WE09 Handout Introducing the PrEP Package for Enhanced HIV Prevention: A Practical Guide for Clinicians Although advances in treatment have improved the quality and length of life for individuals infected

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Acute GVHD: Grading and Endpoints

Acute GVHD: Grading and Endpoints Acute GVHD: Grading and Endpoints Paul Martin, MD Fred Hutchinson Cancer Research Center, Seattle, WA Disclosures Contract support for clinical trials Osiris: Mesenchymal stem cells for secondary treatment

More information

OFFICE OF INSPECTOR GENERAL SPECIAL FRAUD ALERT FRAUD AND ABUSE IN NURSING HOME ARRANGEMENTS WITH HOSPICES

OFFICE OF INSPECTOR GENERAL SPECIAL FRAUD ALERT FRAUD AND ABUSE IN NURSING HOME ARRANGEMENTS WITH HOSPICES OFFICE OF INSPECTOR GENERAL SPECIAL FRAUD ALERT FRAUD AND ABUSE IN NURSING HOME ARRANGEMENTS WITH HOSPICES March 1998 The Office of Inspector General was established at the Department of Health and Human

More information

Who provides this training? Are there any requirements? The parents/guardians and the doctor go through the medication curriculum with the student.

Who provides this training? Are there any requirements? The parents/guardians and the doctor go through the medication curriculum with the student. AL AK AZ AR Student, if they have a chronic condition school nurse or school administrators The student, if their parent/guardian authorizes them to. Trained school personnel can also administer Students

More information

Medical School Math Requirements and Recommendations

Medical School Math Requirements and Recommendations Medical School Math Requirements and Recommendations All information in this document comes from the 2011-2012 Medical School Admission Requirements book (commonly known as the MSAR). Students should check

More information

The Trial to Assess Chelation Therapy (TACT)

The Trial to Assess Chelation Therapy (TACT) The Trial to Assess Chelation Therapy (TACT) Chelation-Placebo Comparison Gervasio A. Lamas MD Professor of Clinical Medicine Columbia University Division of Cardiology Mount Sinai Medical Center Miami

More information

TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG

TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG Tx CENTERS Tuberculosis Control Program Health and Human Services Agency San Diego County INTRODUCTION Reducing TB disease requires

More information

Required Minimum Distribution Election Form for IRA s, 403(b)/TSA and other Qualified Plans

Required Minimum Distribution Election Form for IRA s, 403(b)/TSA and other Qualified Plans Required Minimum Distribution Election Form for IRA s, 403(b)/TSA and other Qualified Plans For Policyholders who have not annuitized their deferred annuity contracts Zurich American Life Insurance Company

More information

2.0 Synopsis. Adalimumab M Clinical Study Report R&D/05/712. (For National Authority Use Only) to Part of Dossier: Volume:

2.0 Synopsis. Adalimumab M Clinical Study Report R&D/05/712. (For National Authority Use Only) to Part of Dossier: Volume: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only)

More information

Brief Communications. Awad Mohamed Ahmed, MD. Abstract

Brief Communications. Awad Mohamed Ahmed, MD. Abstract Awad Mohamed Ahmed, MD Professor of Medicine, University of Bahr Elghazal, Khartoum, Sudan For correspondence Professor Awad Mohamed Ahmed E-mail: awad.sd@gmail.com Tel.: +249 912344936 Abstract Randomized

More information

Ebola: Teaching Points for Nurse Educators

Ebola: Teaching Points for Nurse Educators Ebola: Teaching Points for Nurse Educators Heightened media attention on emerging disease outbreaks such as Ebola may raise concerns among students. During outbreaks such as Ebola, nursing faculty are

More information

What is meant by "randomization"? (Select the one best answer.)

What is meant by randomization? (Select the one best answer.) Preview: Post-class quiz 5 - Clinical Trials Question 1 What is meant by "randomization"? (Select the one best answer.) Question 2 A. Selection of subjects at random. B. Randomization is a method of allocating

More information

Post-Secondary Schools Offering Undergraduate Programs Including Arabic Language/Literature. University name Location Degree offered

Post-Secondary Schools Offering Undergraduate Programs Including Arabic Language/Literature. University name Location Degree offered Post-Secondary Schools Offering Undergraduate Programs Including Arabic Language/Literature University name Location Degree offered Abilene Christian University Abilene, TX None (Special Dialektos Program)

More information

Decision Analysis Example

Decision Analysis Example Options for Doing Cost-Effectiveness Analysis Decision Analysis Example after Occupational Exposure to Clinical trial Mathematical modeling Clinical Trial Incremental Cost-Effectiveness Ratio Conduct a

More information

Exposure. What Healthcare Personnel Need to Know

Exposure. What Healthcare Personnel Need to Know Information from the Centers for Disease Control and Prevention National Center for Infectious Diseases Divison of Healthcare Quality Promotion and Division of Viral Hepatitis For additional brochures

More information

POTENTIAL DENTAL STUDENT ANALYSIS: AVAILABILITY, QUALITY, AND AFFORDABILITY

POTENTIAL DENTAL STUDENT ANALYSIS: AVAILABILITY, QUALITY, AND AFFORDABILITY POTENTIAL DENTAL STUDENT ANALYSIS: AVAILABILITY, QUALITY, AND AFFORDABILITY Robert L. Armacost, D.Sc. Special Advisor to the Dean College of Medicine University of Central Florida July 2011 POTENTIAL

More information

Rates are valid through March 31, 2014.

Rates are valid through March 31, 2014. The data in this chart was compiled from the physician fee schedule information posted on the CMS website as of January 2014. CPT codes and descriptions are copyright 2012 American Medical Association.

More information

Palliative Care/Pain Management Training Programs

Palliative Care/Pain Management Training Programs Palliative Care/Pain Management Training Programs Distributed by the CITY OF HOPE PAIN/PALLIATIVE CARE RESOURCE CENTER 1998 Role Modeling Programs* Role modeling is a method used to change practice behavior

More information

50-State Analysis. School Attendance Age Limits. 700 Broadway, Suite 810 Denver, CO 80203-3442 303.299.3600 Fax: 303.296.8332

50-State Analysis. School Attendance Age Limits. 700 Broadway, Suite 810 Denver, CO 80203-3442 303.299.3600 Fax: 303.296.8332 0-State Analysis School Attendance Age Limits 700 Broadway, Suite 810 Denver, CO 80203-32 303.299.3600 Fax: 303.296.8332 Introduction School Attendance Age Limits By Marga Mikulecky April 2013 This 0-State

More information

Demographia City Sector Model Metropolitan Area Maps

Demographia City Sector Model Metropolitan Area Maps Demographia City Sector Model Metropolitan Area Maps Functional Classifications of Sectors in US Metropolitan Areas Functional Classifications Based on 2010 Census July 2014 CITY SECTOR MODEL METROPOLITAN

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE May 11, 2015 SUBJECT EFFECTIVE DATE May 18, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Multiple Sclerosis Agents Pharmacy Service Leesa M. Allen, Deputy Secretary

More information

Exjade Jadenu. Exjade (tablets for oral suspension), Jadenu (deferasirox) Description

Exjade Jadenu. Exjade (tablets for oral suspension), Jadenu (deferasirox) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.11.02 Subject: Exjade Jadenu Page: 1 of 5 Last Review Date: June 19, 2015 Exjade Jadenu Description Exjade

More information